FDA approved a new antibiotic to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).
In the past week, the migraine prevention drug market has suddenly heated up, with 2 new approvals by FDA.
Here are the top 3 new approvals from FDA.
While Teva Pharmaceutical’s new migraine prevention drug is unique, it faces competition from another major migraine treatment.
Pharmacy and healthcare experts cautiously praised the planned development of a fast-acting, better version of naloxone (Narcan), which is used to reverse the effects of opioid overdoses.
FDA okayed a first-of-its-kind treatment for hairy cell leukemia (HCL).
FDA cleared the first and only easy-to-swallow liquid drug to treat amyotrophic lateral sclerosis (ALS).
FDA recently approved a new treatment for 2 rare types of non-Hodgkin lymphomas, as well as a new drug to treat hereditary angiodema and 1 for Fabry disease. Here are the top three new drugs to treat rare diseases.
FDA clears first-of-its-kind gene therapy for rare disease.
While FDA approved the first generic version of epinephrine (EpiPen and EpiPen Jr, Mylan), the new product is not yet on the market.